**Supplementary table 1**: List of significant (p<0.05) prognostic factors in univariable analysis expressed by HR and p-value. In the comparison among more than 2 groups, p-value is reported instead of HR.

|  |  |  |  |
| --- | --- | --- | --- |
| **Univariable analysis** | All patients  (n = 110) | Lung SBRT  (n = 66) | Liver SBRT  (n = 44) |
| **Local control** |  |  |  |
| liver location | 4.66 (1.48, 14.71) | ---------- | ---------- |
| colorectal cancer | >10 | >10 | >10 |
| adenocarcinoma | >10 | >10 |  |
| non – OD at initial diagnosis | 0.20 (0.07, 0.55) | 0.05 (0.00, 0.54) | - |
| BED10 (150-170) |  | - | 0.14 (0.02, 1.14) |
| chemo/targeted therapy after SBRT | - | - | 0.10 (0.02, 0.49) |
| **Overall survival** |  |  |  |
| liver location | 2.97 (1.16, 7.60) | --------- | -------- |
| PTV volume (20 ccm) | 1.35 (1.09, 1.69) | - | 1.36 (1.00, 1.85) |
| **Distal progression** |  |  |  |
| age (10 years) | 0.70 (0.56, 0.86) | 0.66 (0.46, 0.95) | - |
| liver location | 1.98 (1.24, 3.16) | ---------- | --------- |
| non – OD at initial diagnosis | 0.50 (0.30, 0.85) | - | - |
| non – first OD at patient´s HPI | 2.09 (1.23, 3.54) | - | 2.77 (1.31, 5.85) |
| polymetastatic disease at patient´s HPI | 3.05 (1.85, 5.02) | 2.62 (1.25, 5.50) | 3.25 (1.55, 6.81) |
| progression of MTS on previous systemic therapy | 2.04 (1.19, 3.50) | - | 2.22 (1.06, 4.66) |
| BED10 (150-170) | - | - |  |
| **Freedom from widespread dissemination (FFWD)** |  |  |  |
| age (10 years) | 0.76 (0.59, 0.98) | - | - |
| liver location | 2.88 (1.57, 5.28) | ----------- | --------- |
| colorectal cancer | 2.27 (1.20, 4.30) | - | - |
| non – OD at initial diagnosis | 0.35 (0.19, 0.64) | 0.19 (0.06, 0.63) | - |
| non – first OD at patient´s HPI | 2.31 (1.17, 4.56) | - | 2.37 (1.03, 5.45) |
| polymetastatic disease at patient´s HPI | 4.70 (2.57, 8.60) | 5.20 (1.88, 14.36) | 3.78 (1.72, 8.27) |
| progression of MTS on previous systemic therapy | 3.29 (1.73, 6.27) | 4.71 (1.64, 13.50) |  |
| **Freedom from the need of subsequent treatment (FFNT)** |  |  |  |
| Age (10 years) | 0.72 (0.58, 0.89) | 0.68 (0.48, 0.98) | - |
| liver location | 1.86 (1.17, 2.96) | ---------- | ---------- |
| non – OD at initial diagnosis | 0.49 (0.29, 0.83) | - | - |
| non – first OD at patient´s HPI | 1.98 (1.18, 3.33) | - | 2.73 (1.29, 5.75) |
| polymetastatic disease at patient´s HPI | 2.87 (1.74, 4.74) | 2.41 (1.15, 5.06) | 3.16 (1.52, 6.58) |
| progression of MTS on previous systemic therapy | 2.44 (1.43, 4.18) | - | 2.70 (1.28, 5.73) |
| **Functional survival** |  |  |  |
| adenocarcinoma | 2.64 (1.15, 6.03) |  | - |
| non – OD at initial diagnosis | - | - |  |
| volume of PTV (20 ccm) | 1.27 (1.04, 1.56) | - | 1.50 (1.10, 2.04) |

Abbreviations: SBRT: stereotactic body radiation therapy, HR: hazard ratio, OD: oligometastatic disease, BED10: biological effective dose when α/β equals 10, PTV: planning target volume, PTV: planning target volume, ITV: internal target volume, Dmin\_ITV: minimal dose in ITV, Dmin\_PTV: minimal dose in PTV, HPI: history of patient´s illness, MTS: metastasis.